FDA: Compounding Limited When Approved Drugs Available
The U.S. Food and Drug Administration has proposed removing key active ingredients used in popular obesity and diabetes treatments from its bulk drug substances list, a move that would further limit the ability of outsourcing facilities to produce compounded versions of such medications. In a statement, FDA Commissioner Marty Makary said the proposal aligns with…
